GB8504099D0
(en)
|
1985-02-18 |
1985-03-20 |
Wellcome Found |
Physiologically active substances
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
GB8610551D0
(en)
|
1986-04-30 |
1986-06-04 |
Hoffmann La Roche |
Polypeptide & protein derivatives
|
JPH0665280B2
(ja)
|
1987-03-04 |
1994-08-24 |
味の素株式会社 |
タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
|
DE68929273T2
(de)
|
1988-08-24 |
2001-07-05 |
American Cyanamid Co |
Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
|
CA2345497A1
(en)
|
1988-10-28 |
1990-04-28 |
Genentech, Inc. |
Growth hormone variants and method for forming growth hormone variants
|
US5534617A
(en)
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
DE68929217T2
(de)
|
1989-03-20 |
2000-11-30 |
Gen Hospital Corp |
Insulinotropes hormon
|
US5101018A
(en)
|
1989-06-12 |
1992-03-31 |
International Minerals & Chemical Corp. |
Method for recovering recombinant proteins
|
DE3930696A1
(de)
|
1989-09-14 |
1991-03-28 |
Hoechst Ag |
Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
ATE164852T1
(de)
|
1990-01-24 |
1998-04-15 |
Douglas I Buckley |
Glp-1-analoga verwendbar in der diabetesbehandlung
|
US5951972A
(en)
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
JP2849773B2
(ja)
|
1990-08-27 |
1999-01-27 |
天野製薬株式会社 |
ストレプトミセス属由来のトランスグルタミナーゼの製造法
|
DK220890D0
(da)
|
1990-09-14 |
1990-09-14 |
Ole Buchardt |
Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
JP3267293B2
(ja)
*
|
1990-12-03 |
2002-03-18 |
ジェネンテク,インコーポレイテッド |
改変された結合性を有する変異タンパク質の豊富化法
|
IT1251895B
(it)
|
1991-09-27 |
1995-05-26 |
Eniricerche Spa |
Mutanti dell'ormone della crescita umano e loro impiego
|
DE69333718T2
(de)
|
1992-01-14 |
2005-12-01 |
Ajinomoto Co., Inc. |
Gen, das für eine Fisch-Transglutaminase kodiert
|
NZ255158A
(en)
|
1992-07-31 |
1997-09-22 |
Genentech Inc |
Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it
|
ZA936811B
(en)
|
1992-10-28 |
1995-03-15 |
Upjohn Co |
Somatotropin modifications
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
US5736356A
(en)
|
1994-01-28 |
1998-04-07 |
Ajinomoto Co., Inc. |
Transglutaminase originating from Crassostrea gigas
|
JP3720363B2
(ja)
|
1994-08-26 |
2005-11-24 |
ノボザイムス アクティーゼルスカブ |
微生物のトランスグルタミナーゼ、それらの産生及び使用
|
WO1996010089A1
(fr)
|
1994-09-29 |
1996-04-04 |
Ajinomoto Co., Inc. |
Modification d'un peptide et d'une proteine
|
DE4437604A1
(de)
|
1994-10-21 |
1996-04-25 |
Basf Ag |
Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
|
EP0871712B1
(en)
|
1995-01-19 |
2003-08-27 |
Novozymes A/S |
Transglutaminases from oomycetes
|
JP3669390B2
(ja)
|
1995-02-09 |
2005-07-06 |
味の素株式会社 |
バチルス属細菌由来のトランスグルタミナーゼ
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
CA2658039A1
(en)
*
|
1995-09-21 |
1997-03-27 |
Genentech, Inc. |
Human growth hormone variants
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
IL128332A0
(en)
|
1996-08-30 |
2000-01-31 |
Novo Nordisk As |
GLP-1 derivatives
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
EP0929576A1
(en)
|
1996-08-30 |
1999-07-21 |
Novo Nordisk A/S |
Glp-2 derivatives
|
WO1998013381A1
(fr)
|
1996-09-26 |
1998-04-02 |
Ajinomoto Co., Inc. |
Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
|
US5985627A
(en)
|
1997-02-28 |
1999-11-16 |
Carlsberg Laboratory |
Modified carboxypeptidase
|
JPH1156378A
(ja)
*
|
1997-06-11 |
1999-03-02 |
Nippon Chem Res Kk |
変異型ヒト成長ホルモンとその用途
|
IL133686A0
(en)
|
1997-06-25 |
2001-04-30 |
Applied Research Systems |
Glycoprotein hormone analogs, their preparation and use
|
NZ502375A
(en)
|
1997-07-14 |
2001-11-30 |
Bolder Biotechnology Inc |
The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
|
JPH1192499A
(ja)
*
|
1997-09-22 |
1999-04-06 |
Sumitomo Pharmaceut Co Ltd |
ヒト成長ホルモン変異体
|
US6136536A
(en)
|
1997-10-29 |
2000-10-24 |
Genetics Institute, Inc. |
Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
WO1999043705A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
WO1999043341A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
|
JP2003522099A
(ja)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
|
JP2002504527A
(ja)
|
1998-02-27 |
2002-02-12 |
ノボ ノルディスク アクティーゼルスカブ |
部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体
|
US6656922B2
(en)
|
1998-05-28 |
2003-12-02 |
Mediplex Corporation, Korea |
Oral delivery of macromolecules
|
US6358705B1
(en)
|
1998-07-16 |
2002-03-19 |
Novo Nordisk A/S |
Method of making proteins in transformed yeast cells
|
KR100511855B1
(ko)
|
1998-12-07 |
2005-09-02 |
소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. |
Glp-1의 유사체
|
EA003922B1
(ru)
|
1999-05-17 |
2003-10-30 |
Конджачем, Инк. |
Продолжительно действующие инсулинотропные пептиды
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
EP1198565A1
(en)
|
1999-07-07 |
2002-04-24 |
Maxygen Aps |
A method for preparing modified polypeptides
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB2355009A
(en)
|
1999-07-30 |
2001-04-11 |
Univ Glasgow |
Peptides conjugated to bile acids/salts
|
US20040001827A1
(en)
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
WO2001051071A2
(en)
|
2000-01-11 |
2001-07-19 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
IL150692A0
(en)
|
2000-02-11 |
2003-02-12 |
Maxygen Aps |
FACTOR VII OR VIIa-LIKE MOLECULES
|
JP2003530847A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
CA2408851C
(en)
*
|
2000-05-16 |
2011-07-12 |
Bolder Biotechnology, Inc. |
Methods for refolding proteins containing free cysteine residues
|
US20020142964A1
(en)
|
2000-11-02 |
2002-10-03 |
Nissen Torben Lauesgaard |
Single-chain polypeptides
|
DK1724284T3
(da)
|
2000-12-07 |
2009-11-02 |
Lilly Co Eli |
GLP-1 fusionsproteiner
|
JP2004524020A
(ja)
*
|
2001-01-11 |
2004-08-12 |
マキシゲン・エイピーエス |
改良された成長ホルモン分子
|
US20060183197A1
(en)
|
2001-01-11 |
2006-08-17 |
Andersen Kim V |
Variant growth hormone molecules conjugated with macromolecules compounds
|
FR2819810B1
(fr)
|
2001-01-23 |
2004-05-28 |
Pf Medicament |
Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7205278B2
(en)
|
2001-06-14 |
2007-04-17 |
The Scripps Research Institute |
Stabilized proteins with engineered disulfide bonds
|
US20030119734A1
(en)
|
2001-06-28 |
2003-06-26 |
Flink James M. |
Stable formulation of modified GLP-1
|
US7186797B2
(en)
|
2001-08-10 |
2007-03-06 |
Epix Pharmaceuticals, Inc. |
Polypeptide conjugates with extended circulating half-lives
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
US20050233417A1
(en)
|
2001-11-12 |
2005-10-20 |
Cooper David N |
Growth hormone variations in humans and their uses
|
CA2467731A1
(en)
|
2001-11-20 |
2003-05-30 |
Pharmacia Corporation |
Chemically-modified human growth hormone conjugates
|
JP2003199569A
(ja)
|
2001-12-17 |
2003-07-15 |
Food Industry Research & Development Inst |
ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
|
FR2836382B1
(fr)
|
2002-02-28 |
2004-08-13 |
Biomerieux Sa |
Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
|
AU2003278807A1
(en)
|
2002-03-01 |
2004-08-13 |
Bracco International B.V. |
Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
|
IL164266A0
(en)
|
2002-04-10 |
2005-12-18 |
Lilly Co Eli |
Treatment of gastroparesis
|
KR101121593B1
(ko)
|
2002-04-30 |
2012-04-12 |
맥시겐 홀딩스 엘티디 |
인자 ⅶ 또는 ⅶ에이 폴리펩티드 변이체
|
CA2498319A1
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
EP2067483A1
(en)
|
2003-02-19 |
2009-06-10 |
Ipsen Pharma |
Analogues of GLP-1
|
JP2007524584A
(ja)
|
2003-05-09 |
2007-08-30 |
ノボ ノルディスク アクティーゼルスカブ |
肥満の治療に使用するペプチド
|
EP1653996A2
(en)
|
2003-08-08 |
2006-05-10 |
Novo Nordisk Health Care AG |
Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
|
RU2401276C2
(ru)
|
2003-09-19 |
2010-10-10 |
Ново Нордиск А/С |
Производные глюкагон-подобного пептида-1 (glp-1)
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
EP2932981B1
(en)
|
2003-09-19 |
2021-06-16 |
Novo Nordisk A/S |
Albumin-binding derivatives of GLP-1
|
CN100444898C
(zh)
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
EP1673464A2
(en)
|
2003-10-10 |
2006-06-28 |
Novo Nordisk A/S |
Conjugation of peptides
|
KR20060109940A
(ko)
|
2003-12-18 |
2006-10-23 |
노보 노르디스크 에이/에스 |
알부민-유사제에 연결된 신규 glp-1 유사체
|
DE602004026113D1
(de)
|
2003-12-18 |
2010-04-29 |
Novo Nordisk As |
Glp-1-verbindungen
|
MXPA06008209A
(es)
|
2004-01-21 |
2006-08-31 |
Novo Nordisk As |
Conjugacion de peptidos mediada por transglutaminasa.
|
MXPA06008507A
(es)
|
2004-02-02 |
2008-02-13 |
Ambrx Inc |
Cuatro polipeptidos en haz helicoidal humanos modificados y sus usos.
|
ATE547121T1
(de)
|
2004-04-07 |
2012-03-15 |
Ares Trading Sa |
Flüssigformulierung für wachstumshormone
|
US7906137B2
(en)
|
2004-05-21 |
2011-03-15 |
Mediplex Corporation, Korea |
Delivery agents for enhancing mucosal absorption of therapeutic agents
|
WO2006005667A2
(en)
|
2004-07-08 |
2006-01-19 |
Novo Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
EP1778838A2
(en)
|
2004-08-02 |
2007-05-02 |
Novo Nordisk Health Care AG |
Conjugation of fvii
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
WO2006071840A2
(en)
|
2004-12-22 |
2006-07-06 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
RU2007134155A
(ru)
|
2005-03-18 |
2009-04-27 |
Ново Нордиск А/С (DK) |
Glp-1 соединения с увеличенным временем полужизни
|
WO2006097536A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
US20090117640A1
(en)
|
2005-08-18 |
2009-05-07 |
Novo Nordisk Health Care Ag |
Transglutaminase Variants with Improved Specificity
|
EP1928906A2
(en)
|
2005-08-30 |
2008-06-11 |
Novo Nordisk Health Care AG |
Liquid formulations of pegylated growth hormone
|
CN1939534B
(zh)
|
2005-09-27 |
2010-12-01 |
长春金赛药业股份有限公司 |
含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
|
WO2007094916A2
(en)
*
|
2006-01-19 |
2007-08-23 |
Ambrx, Inc. |
Non-natural amino acid polypeptides having modulated immunogenicity
|
ES2546282T3
(es)
|
2006-02-14 |
2015-09-22 |
Novo Nordisk Health Care Ag |
Acoplamiento de polipéptidos en el extremo C-terminal
|
WO2008003750A2
(en)
|
2006-07-07 |
2008-01-10 |
Novo Nordisk Health Care Ag |
New protein conjugates and methods for their preparation
|
WO2008014430A1
(en)
|
2006-07-27 |
2008-01-31 |
Emisphere Technologies, Inc. |
Arylsulfanyl compounds and compositions for delivering active agents
|
CN101506233A
(zh)
|
2006-08-18 |
2009-08-12 |
诺沃-诺迪斯克保健股份有限公司 |
具有提高的特异性的转谷氨酰胺酶变异体
|
US8323688B2
(en)
|
2006-08-31 |
2012-12-04 |
Novartis Ag |
Pharmaceutical compositions comprising hGH for oral delivery
|
US20080095837A1
(en)
|
2006-08-31 |
2008-04-24 |
Emisphere Technologies, Inc. |
Human growth hormone formulations
|
WO2008101240A1
(en)
|
2007-02-16 |
2008-08-21 |
Emisphere Technologies, Inc. |
Compounds having a cyclic moiety and compositions for delivering active agents
|
WO2008112836A2
(en)
|
2007-03-15 |
2008-09-18 |
Novartis Ag |
Pharmaceutical composition comprising human growth hormon
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
US8865868B2
(en)
|
2008-08-06 |
2014-10-21 |
Novo Nordisk Healthcare Ag |
Conjugated proteins with prolonged in vivo efficacy
|
CN102149726A
(zh)
|
2008-09-09 |
2011-08-10 |
诺沃—诺迪斯克保健股份有限公司 |
稳定性提高的生长激素共轭物
|
JP5591243B2
(ja)
|
2008-09-12 |
2014-09-17 |
ノボ・ノルデイスク・エー/エス |
ペプチド又はタンパク質のアシル化の方法
|
ES2542202T3
(es)
|
2009-01-22 |
2015-08-03 |
Novo Nordisk Health Care Ag |
Compuestos de hormonas de crecimiento estables
|
CN102333788A
(zh)
|
2009-02-19 |
2012-01-25 |
诺沃—诺迪斯克有限公司 |
因子viii的修饰
|
WO2011015649A1
(en)
|
2009-08-06 |
2011-02-10 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
BR112012018162A2
(pt)
|
2010-01-22 |
2017-10-03 |
Novo Nordisk Healthcare Ag |
Compostos de hormônio do crescimento estáveis
|
JP5875527B2
(ja)
|
2010-01-22 |
2016-03-02 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
in−vivoにおける効力が延長された成長ホルモン
|
US20130012684A1
(en)
|
2010-02-16 |
2013-01-10 |
Novo Nordisk A/S |
Purification Method
|